

Workshop

PPARs: LIPID AND LIPOPROTEIN METABOLISM

Chairpersons: **Ginsberg H.N.** (New York, USA)
Grimaldi P.A. (Nice, France)

hour:		abstract bk. page ref.:
17.00 – 17.20	REGULATION OF PPAR-gamma-MEDIATED GENE EXPRESSION: A NEW MECHANISM OF ACTION FOR HIGH DENSITY LIPOPROTEIN Hajjar D.P. , Han J., Nicholson A.C., Gotto A.M., Jr. (New York, USA)	3
17.20 – 17.40	EFFECTS OF THIAZOLIDINEDIONES ON LIPOPROTEIN METABOLISM Ginsberg H.N. , Nagashima K., Lopez C., Donovan D., Ko C., Huang L.-S. (New York, USA)	3
17.40 – 17.55	THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR gamma COORDINATELY REGULATES MEMBERS OF THE LIPID DROPLET ASSOCIATING PROTEIN GENE FAMILY Dalen K.T. , Schoonjans K., Weedon M.S., Bentzen T.G., Koutnikova H., Ulven S.M., Auwerx J., Nebb H.I. (Oslo, Norway, and Illkirch, France)	3
17.55 – 18.10	TROGLITAZONE (TGZ) EXERTS BOTH BENEFICIAL AND UNDESIRABLE EFFECTS ON LIPID METABOLISM IN A HUMAN APOB TRANSGENIC MOUSE MODEL Ko C., McQuade M., Lee T.-L., Ginsberg H., Huang L.-S. (New York, USA)	3
18.10 – 18.25	ABCA1 AND ABCG1, -5, AND -8, ARE REGULATED BY PPAR-delta AND LXR IN CULTURED RAT HEPATOCYTES Spijkers J.A.A. , Hoekstra M., Kruijt J.K., Groot P.H.E., van Berkel T.J.C. (Leiden, Amsterdam, The Netherlands, and Harlow, UK)	4
18.25 – 18.40	OVEREXPRESSION OF A PPAR-alpha DOMINANT NEGATIVE RECEPTOR IN HEPATIC CELL DOES NOT IMPAIR FATTY-ACID INDUCED L-CPTI GENE EXPRESSION Le May C. , Caüzac M., Perdereau D., Burnol A.-F., Girard J., Pégorier J.-P. (Paris, France)	4
18.40	<i>End of the Session</i>	

Workshop

PPARs AND CROSSTALK WITH OTHER NUCLEAR RECEPTORS AND TRANSCRIPTION FACTORS (*First Part*)

Chairpersons: **Tontonoz P.** (Los Angeles, USA)
Crestani M. (Milan, Italy)

hour:		abstract bk. page ref.:
14.00 – 14.20	ROLE OF PPARs AND LXRs IN MACROPHAGE LIPID METABOLISM Tontonoz P. , Joseph S.B., Castrillo A., Laffitte B.A., Walczak R., Hummasti S. (Los Angeles, USA)	4
14.20 – 14.35	INDUCTION OF HEPATIC ABC TRANSPORTER EXPRESSION IS PART OF THE PPAR-alpha-MEDIATED FASTING RESPONSE IN THE MOUSE Kok T. , Wolters H., Bloks V.W., Havinga R., Jansen P.L.M., Staels B., Kuipers F. (Groningen, The Netherlands, and Lille, France)	4
14.35 – 14.50	LXR-DEPENDENT AUTOREGULATION OF 'REVERSE STEROL TRANSPORT' AT AN <i>IN VITRO</i> BLOOD BRAIN BARRIER Panzenboeck U. , Balazs Z., Sovic A., Hrzenjak A., Wintersperger A., Sattler W. (Graz, Austria)	5
14.50 – 15.05	THE ROLE OF FXR IN LIVER SR-BI EXPRESSION Out R. , Spijkers J.A.A., Hoekstra M., Kroeze K., van Berkel T.J.C. (Leiden and Amsterdam, The Netherlands)	5
15.05	<i>End of the Session</i>	
15.05 – 15.45	<i>Break</i>	
15.45 - 16.45	<i>POSTER DISCUSSION AT THE POSTER SITE WITH THE AUTHORS Group A (Poster Sessions 1 – 6; see Final Programme Pages 23 - 31)</i>	

Workshop

PPARs AND CROSSTALK WITH OTHER NUCLEAR RECEPTORS AND TRANSCRIPTION FACTORS (*Second Part*)

Chairpersons: **Tontonoz P.** (Los Angeles, USA)
Crestani M. (Milan, Italy)

hour:		abstract bk. page ref.:
17.00 – 17.20	ROLE OF NUCLEAR RECEPTORS IN REVERSE CHOLESTEROL TRANSPORT Crestani M. , De Fabiani E., Mitro N., Caruso D., Patelli R., Pinelli A., Galli G. (Milan, Italy)	5
17.20 – 17.35	KINASE-INDEPENDENT TRANSCRIPTIONAL COACTIVATION OF PPAR-alpha BY AMP-ACTIVATED PROTEIN KINASE Bronner M. , Hertz R., Bar-tana J. (Jerusalem, Israel)	5
17.35 – 17.50	MAPPING THE INTERACTION BETWEEN PPAR-gamma AND TRANSCRIPTIONAL COREGULATORS Smith A.G. , Agostini M., Gurnell M., Schwabe J.W.R., Chatterjee V.K.K. (Cambridge, UK)	6
17.50 – 18.05	DIFFERENTIAL EFFECTS OF FENOFIBRATE AND REXINOIDS ON AN ARRAY OF CLASS II NUCLEAR RECEPTOR-TARGET GENES Martin P. , Ouamrane L., Lasserre F., Calleja C., Van Es A., Roulet A., Gauthier B., Pineau T. (Toulouse and Sophia Antipolis, France)	6
18.05 – 18.20	HUMAN UNCOUPLING PROTEIN-3 GENE TRANSCRIPTION IN MUSCLE: FUNCTIONAL RELATIONSHIP BETWEEN MyoD AND PPAR-DEPENDENT REGULATORY PATHWAYS Pedraza N., Iglesias R., Giralt M., Villarroya F., Solanes G. (Barcelona, Spain)	6
18.20	<i>End of the Session</i>	

Workshop

CELL CYCLE, DIFFERENTIATION, AND CANCER

Chairpersons: **Gupta R.A.** (Nashville, USA)
Reddy J.K. (Chicago, USA)

hour:		abstract bk. page ref.:
14.00 – 14.20	GENE EXPRESSION PROFILES IN LIVER DURING PPAR-alpha ACTIVATION Reddy J.K. (Chicago, USA)	6
14.20 – 14.40	BIOLOGICAL ACTIVITIES OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR SUBTYPES –gamma AND –delta IN COLORECTAL CANCER Gupta R.A. , DuBois R.N. (Nashville, USA)	7
14.40 – 14.55	IDENTIFICATION AND CHARACTERIZATION OF G0/G1 SWITCH GENE 2 (G0S2), A PPAR-REGULATED GENE IMPLICATED IN CELL CYCLE AND ADIPOGENESIS Zandbergen F.J., Escher P., Mandard S., Rieusset J., Desvergne B., Tafuri S., Wahli W., Müller M., Kersten S. (Wageningen, The Netherlands)	7
14.55 – 15.10	FUNCTIONAL INTERACTIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-gamma AND CAVEOLINS IN MULTIDRUG RESISTANT HUMAN CANCER CELLS Burgermeister E. , Tencer L., Liscovitch M. (Rehovot, Israel)	7
15.10 – 15.25	PPAR-delta IS REQUIRED FOR THE DIFFERENTIATION OF THP-1 MONOCYTIC CELLS BY PHORBOL ESTER Vosper H., Khoudoli G.A., Graham T.L., Palmer C.N.A. (Dundee, Scotland)	7
15.25 – 15.40	EFFECT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR gamma LIGANDS ON NORMAL AND NEOPLASTIC HUMAN UROTHELIAL CELL GROWTH Spencer P.A. , Holder J.C., Southgate J. (York and Welwyn, UK)	8
15.40	<i>End of the Session</i>	
15.45 - 16.45	<i>POSTER DISCUSSION AT THE POSTER SITE WITH THE AUTHORS Group A (Poster Sessions 1 – 6; see Final Programme Pages 23 - 31)</i>	

Workshop

PPARs AND THE CARDIOVASCULAR SYSTEM

Chairpersons: **Demarest K.** (Raritan, USA)
Kelly D.P. (St. Louis, USA)

hour:		abstract bk. page ref.:
14.00 – 14.20	PPAR-gamma LIGAND REGULATION OF CELL CYCLE IN VSMC-RECEPTOR: DEPENDENT OR INDEPENDENT? Law R.E. (Los Angeles, USA)	10
14.20 – 14.35	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha PLAYS AN IMPORTANT ROLE IN INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION AFTER VASCULAR INJURY Wang K. , Zhou X., Fan L., Zhou Z., Lincoff A.M., Topol E.J., Penn M.S. (Cleveland, USA)	10
14.35 – 14.50	ACTIVATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-alpha AND -gamma IN AURICULAR TISSUE FROM PATIENTS WITH HUMAN FAILING HEART DUE TO ISCHEMIC CARDIOMYOPATHY Gómez-Garre D., Bernal R., Herraiz M., González-Rubio M.L., Aragoncillo P., Carbonel A., Rupilanchas J., Fernández-Cruz A. (Madrid, Spain)	10
14.50 – 15.05	EFFECT OF PROSTAGLANDIN-J ₂ ON SYNTHESIS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IS OPPOSITE IN NORMOXIA AND HYPOXIA Jozkowicz A. , Huk I., Nigisch A., Weigel G., Dulak J. (Vienna, Austria and Kraków, Poland)	10
15.05 – 15.20	THE VASCULAR/PULMONARY CYTOCHROME P450 CYP2J2 IS A NOVEL SOURCE OF PPAR-alpha LIGANDS Bishop-Bailey D. , Wray J., Zeldin D., Warner T.D. (London, UK and Research Triangle Park, USA)	11
15.20 – 15.35	THE ROLE OF PPAR-alpha IN THE PROTECTION AGAINST CARDIAC LIPOTOXICITY Leone T.C. , Schaffer J.E., Chiu H.-C., Weinheimer C.J., Courtois M.R., Kovacs A., Kelly D.P. (St. Louis, USA)	11
15.35	<i>End of the Session</i>	
15.35 – 16.00	<i>Break</i>	

Workshop

PPARs IN DERMATOLOGY

Chairpersons: **Peters J.M.** (University Park, USA)
Wahli W. (Lausanne, Switzerland)

hour:		abstract bk. page ref.:
16.00 – 16.15	EXPRESSION AND LOCALIZATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS AND NUCLEAR FACTOR KAPPA B IN NORMAL AND LESIONAL PSORIATIC SKIN Westergaard M., Henningsen J., Johansen C., Rasmussen S., Svendsen M.L., Jensen U.B., Schrøder H.D., Staels B., Iversen L., Bolund L., Kragballe K., Kristiansen K. (Odense, Århus, Denmark, and Lille, France)	11
16.15 – 16.30	NOVEL PPAR-gamma LIGANDS FOR TOPICAL TREATMENT OF INFLAMMATORY & PROLIFERATIVE DISEASES OF SKIN Pershadsingh H.A., Venkatraman M., Chittiboyina A., Avery M., Benson S., Ho C., Varani J., Ellis C., Kurtz T. (Mill Valley, Oxford, Hayward, Ann Arbor, and San Francisco, USA)	11
16.30 – 16.45	DIFFERENTIATION AND LIPID ACCUMULATION IN PPAR-delta TREATED KERATINOCYTES Schmuth M. , Lau P., Schoonjans K., Auwerx J., Chambon P., Willson T.M., Elias P.M., Feingold K.R. (San Francisco, Research Triangle Park, USA, and Illkirch, France)	12
16.45 – 17.00	NOVEL DERIVATIVES OF alpha-LIPOIC ACID WITH IMPROVED PPAR-gamma AND ANTIOXIDANT ACTIVITY Pershadsingh H.A. , Ho C., Chittiboyina A., Avery M.A., Kurtz T., Benson S.C. (Bakersfield, University, Hayward, and Mill Valley, USA)	12
17.00 – 17.15	THE DNA REPAIR/TRANSCRIPTION FACTOR TFIID CONTROLS THE TRANSACTIVATION BY THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS Compe E. , Egly J.-M. (Illkirch, France)	12
17.15	<i>End of the Session</i>	

Workshop

PPARs IN ATHEROSCLEROSIS

Chairpersons: **Marx N.** (Ulm, Germany)**Catapano A.L.** (Milan, Italy)

hour:		abstract bk. page ref.:
14.00 – 14.20	PPARs IN THE VASCULATURE - FROM BENCH TO BEDSIDE Marx N. (Ulm, Germany)	12
14.20 – 14.40	PPARs: KEY REGULATORS OF MACROPHAGE CHOLESTEROL HOMEOSTASIS Chinetti G. (Lille, France)	13
14.40 – 14.55	MACROPHAGE EXPRESSION OF PPAR-alpha INHIBITS ATHEROSCLEROTIC LESION FORMATION IN LDL-RECEPTOR DEFICIENT MICE Linton M.F. , Babaev V.R., Dove D.E., Fazio S., Semenkovich C.F. (Nashville and St. Louis, USA)	13
14.55 – 15.10	IDENTIFICATION OF TWO FUNCTIONAL PEROXISOMAL PROLIFERATOR RESPONSE ELEMENTS IN THE HUMAN TNF-alpha PROMOTER Cabré A. , Girona J., Fajas L., Zalba G., Vallvé J.-C., Díez J., Masana L. (Reus, Spain, Montpellier, France, and Navarra, Spain)	13
15.10 – 15.25	FENOFIBRATE INHIBITS ANGIOGENESIS <i>IN VITRO</i> AND <i>IN VIVO</i> : A POSSIBLE CONTRIBUTION FOR THE PREVENTION OF VASCULAR RISK Varet J. , Vincent L., Mirshahi P., Pille J.Y., Opolon P., Mishal Z., Soria J., Li H., Soria C. (Rouen, France)	13
15.25	<i>End of the Session</i>	
15.25 – 16.00	<i>Break</i>	

Workshop

PPARs: STRUCTURE AND NEW LIGANDS

Chairpersons: **Camejo G.** (Mölndal, Sweden)
Wassermann K. (Bagsværd, Denmark)

hour:		abstract bk. page ref.:
16.00 – 16.20	PPAR AGONISTS VASCULAR EFFECTS CONTRIBUTING TO THEIR APPARENT ANTI-ATHEROGENIC ACTION Camejo G. , Rosengren B., Hallberg C., Wallin B. (Mölndal, Sweden)	14
16.20 – 16.40	THERAPEUTIC BENEFITS FROM DUAL PPAR-gamma AND PPAR-alpha ACTIVATION Wassermann K. , Ye J.M., Brand C.L., Larsen P.J., Wulff E.M. (Bagsværd, Denmark and Sydney, Australia)	14
16.40 – 17.00	LIGAND SUBTYPE AND SPECIES SELECTIVITY IN PPAR-alpha AND PPAR-gamma DELINEATED BY X-RAY CRYSTALLOGRAPHY AND SITE DIRECTED MUTAGENESIS Davidsson Ö., Kajanus J., Karlsson U., Lindstedt E.-L., Lidberg A.-K., Petersen J., Bamberg K. (Mölndal, Sweden)	14
17.00 – 17.15	FAVORABLE EFFECTS ON LIPID HOMEOSTASIS CAUSED BY A NOVEL PPAR-alpha/gamma-DUAL AGONIST Guo Q. , Sahoo S.P., Wang P.-R., Han W., Milot D.P., Ippolito M.C., Berger J.P., Biswas C., Cohen S.M., Doebber T.W., Hernandez M., Kelly L.J., Lam M.-H., MacNaul K.L., Sharma N., Wu M., Zhou G., Heck J.V., Sparrow C.P., Chao Y.-S., Moller D.E., Wright S.D. (Rahway, USA)	14
17.15 – 17.30	PAT5A: A PARTIAL AGONIST/ANTAGONIST OF PPAR-gamma IS A POTENT ANTIDIABETIC THIAZOLIDINEDIONE WITH MINIMAL ADIPOGENISITY Misra P. , Chakrabarti R., Vikramadithyan R.K., Gopalakrishnan B., Suresh J., Jagdeshan H., Cynthia R., Rajjak A., Reddy P.K., Yu S., Surapureddi S., Qi C., Zhu Y.J., Rao M.S., Reddy J.K., Rajagopalan R. (Hyderabad, India and Chicago, USA)	15
17.30 – 17.45	SINGLE DOSES OF MK-0767 (KRP-297) REDUCE FREE FATTY ACIDS (FFA) AND TRIGLYCERIDES (TG) IN HEALTHY SUBJECTS Wagner J.A. , Rippley R.K., Chen X., Miller J.L., Ballaux D., De Smet M., Gottesdiener K.M., Keymeulen B. (Rahway, Westpoint, USA, and Brussels, Belgium)	15
17.45	<i>End of the Session</i>	

Workshop

PPARs IN DIABETES: PRECLINICAL STUDIES

Chairpersons: **Smith U.** (Göteborg, Sweden)
Wassef M. (Bethesda, USA)

hour:		abstract bk. page ref.:
17.00 – 17.20	EFFECT OF PPAR AGONISTS ON GENES RELATED TO INSULIN SIGNALING AND ACTION Smith U. (Göteborg, Sweden)	17
17.20 – 17.35	LIMITATION ON INSULIN RESISTANCE BY PPAR-alpha OVEREXPRESSION Isogai S. , Tsunoda M., Murakami K. (Tochigi, Japan)	17
17.35 – 17.50	ASSOCIATION OF FENOFIBRATE WITH A LOW DOSE OF ROSIGLITAZONE FULLY PREVENTS OVERT DIABETES IN MALE ZDF RATS WITHOUT THE ADVERSE EFFECT OF ROSIGLITAZONE ALONE ON BODY WEIGHT GAIN Aubert M.L. , Sudre B., Vauthay D., Edgar A., Pruneau D., Junien J.L. (Geneva, Switzerland and Daix, France)	17
17.50 – 18.05	ROLE OF PPAR-gamma IN PROTECTION OF beta CELLS IN TYPE II DIABETES Welters H.J. , McBain S.C., Tadayyon M., Scarpello J.H., Smith S.A., Morgan N.G. (Plymouth, Keele and Harlow, UK)	17
18.05 – 18.20	PPAR-alpha AND RXR-alpha SYNERGISTICALLY INCREASE FATTY ACID OXIDATION AND UCP-2 EXPRESSION IN THE PANCREATIC beta-CELL LINE INS-1E - POSSIBLE IMPLICATIONS FOR INSULIN SECRETION Ravnskjær K. , Larsen J.K., Børgesen M., Nielsen R., Maechler P., Mandrup S. (Odense, Denmark and Geneva, Switzerland)	18
18.20 – 18.35	PPAR-alpha ACTIVATES FATTY ACID OXIDATION IN SKELETAL MUSCLE CELLS WITHOUT IMPAIRING GLUCOSE METABOLISM Hondares E., Pineda-Torra I., Iglesias R., Staels B., Villarroya F., Giralt M. (Lille, France and Barcelona, Spain)	18
18.35	<i>End of the Session</i>	

Workshop

PPARs, INFLAMMATION AND IMMUNE RESPONSE

Chairpersons: **Plutzky J.** (Boston, USA)
Trottein F. (Lille, France)

hour:		abstract bk. page ref.:
14.00 – 14.20	PPARs AS MODULATORS OF THE INFLAMMATORY RESPONSE IN THE VASCULATURE: EXOGENOUS AND ENDOGENOUS MECHANISMS Plutzky J. (Boston, USA)	18
14.20 – 14.40	ROLE OF PPAR-gamma IN DENDRITIC CELL FUNCTIONS: CONSEQUENCES ON THE INFLAMMATORY AND IMMUNE RESPONSES Trottein F. (Lille, France)	18
14.40 – 14.55	EVIDENCE THAT ROSIGLITAZONE ACTS AS ANTIDEGRADATIVE AGENT ON CARTILAGE CELLS <i>IN VITRO</i> François M. , Tsagris L., Richette P., Forest C., Raymondjean M., Corvol M.T. (Paris, France)	19
14.55 – 15.10	PPAR SIGNALING AND PROTECTIVE MECHANISMS OF ZINC IN ACTIVATED ENDOTHELIAL CELLS Hennig B. , Toborek M., Meerarani P., Reiterer G. (Lexington, USA)	19
15.10 – 15.25	VASCULAR ANTI-INFLAMMATORY EFFECTS OF TZD's MAY NOT REQUIRE PPAR-gamma ACTIVATION Pal M., Cahoon S., Chakrabarti R., Rao Y.K., Rajagopalan R., Saxena U., Pillarsetti S. (Hyderabad, India and Norcross, USA)	19
15.25 – 15.40	ROLE OF PPAR-gamma LIGAND ROSIGLITAZONE ON THE DEVELOPMENT OF CARRAGEENAN-INDUCED LUNG INJURY Cuzzocrea S. , Dugo L., Di Paola R., Serraino I., Genovese T., Caputi A.P., Thiernemann C. (Messina, Italy and London, UK)	19
15.40	<i>End of the Session</i>	
15.45 – 16.45	<i>POSTER DISCUSSION AT THE POSTER SITE WITH THE AUTHORS Group B (Poster Sessions 7 – 12; see Final Programme Pages 32 - 42)</i>	

Workshop

COMBINED TREATMENTS WITH PPAR LIGANDS AND OTHER DRUGS

Chairpersons: **Farnier M.** (Dijon, France)
Corsini A. (Milan, Italy)

hour:		abstract bk. page ref.:
17.00 – 17.20	COMBINATION THERAPY WITH PPAR AGONISTS IN CLINICAL PRACTICE Farnier M. (Dijon, France)	20
17.20 – 17.35	INTERACTION OF STATINS WITH HYPOLIPIDEMIC AGENTS INCLUDING PPAR AGONISTS Corsini A. , Paoletti R., Bellosta S. (Milan, Italy)	20
17.35 – 17.50	PPAR-alpha DEPENDENT EFFECTS OF ATORVASTATIN ON LIPID METABOLISM IN MICE Johansson L. , Hunt M., Rudling M., Angelin B., Alexsson S., Parini P. (Huddinge and Stockholm, Sweden)	20
17.50 – 18.05	PIOGLITAZONE AND ROFECOXIB COMBINED WITH ANGIOSTATIC SCHEDULING OF CHEMOTHERAPY IN FAR ADVANCED MALIGNANCIES Reichle A. , Bross K., Vogt Th., Bataille F., Wild P., Wodzynski A., Zaiss M., Wagner H., Klebl F., Messmann H., Krause S.W., Dengler R., Andreesen R. (Regensburg, Germany)	20
18.05	<i>End of the Session</i>	

Workshop

PPARs IN OBESITY

Chairpersons: **Farmer S.R.** (Boston, USA)
Taskinen M.-R. (Helsinki, Finland)

hour:		abstract bk. page ref.:
14.00 – 14.20	REGULATION OF PPAR-gamma EXPRESSION AND ACTIVITY DURING ADIPOGENESIS Farmer S.R. , Davis K.E., Li Q., Moldes M., Park B.-H., Silva D., Stevenson M., Zuo Y. (Boston, USA)	21
14.20 – 14.35	THE ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha (PPARalpha) IN ADIPOSE TISSUE Islam K.K. , Frayn K.N., Gibbons G.F., Knight B.L., Patel D. (Nuffield, Oxford, and London, UK)	21
14.35 – 14.50	ENDOGENOUS PPAR-gamma LIGANDS ARE SYNTHESIZED BY A LIPOXYGENASE-DEPENDENT PATHWAY DURING THE INITIAL STAGES OF ADIPOCYTE DIFFERENTIATION Madsen L. , Petersen R.K., Sørensen M.B., Jørgensen C., Hallenborg P., Pridal L., Fleckner J., Amri E.-Z., Krieg P., Berge R.K., Kristiansen K. (Odense, Denmark, Bergen, Norway, Bagsværd, Denmark, Nice, France, and Heidelberg, Germany)	21
14.50 – 15.05	MODULATION OF CIRCULATING AND ADIPOSE TISSUE ADIPONECTIN LEVELS BY ANTI-DIABETIC THERAPY: RELATIONSHIP TO GLYCEMIC CONTROL AND INSULIN ACTION Ciaraldi T.P. , Phillips S.A., Kong A., Bandukwala R., Aroda V., Carter L., Baxi S., Mudaliar S.R., Henry R.R. (San Diego, USA)	21
15.05 – 15.20	PPAR-gamma LIGANDS REVERSE TNF-alpha INDUCTION OF LIPOLYSIS AND INCREASE BASAL AND TNF-alpha-SUPPRESSED ADIPONECTIN SECRETION IN 3T3-L1 ADIPOCYTES Lin P. , Jansen M., Houlihan-Kawamoto C., Pahel G. (Durham, USA)	22
15.20 – 15.35	DIFFERENTIAL MECHANISM FOR FATTY ACID AND THIAZOLIDINEDIONE INDUCTION OF PEPCK-C GENE TRANSCRIPTION IN ADIPOCYTES Duplus E., Glorian M., Forest C. (Paris, France)	22
15.35	<i>End of the Session</i>	
15.35 – 15.45	<i>Break</i>	
15.45 – 16.45	<i>POSTER DISCUSSION AT THE POSTER SITE WITH THE AUTHORS Group B (Poster Sessions 7 - 12; see Final Programme Pages 32 - 42)</i>	

Workshop

PPARs AND GENETICS

Chairpersons: **Flavell D.M.** (London, UK)**O'Rahilly S.** (Cambridge, UK)

hour:		abstract bk. page ref.:
17.00 - 17.20	PPARs, SUBSTRATE UTILISATION AND CARDIAC GROWTH Flavell D.M. , Samuel J., Wootton P., World M., Humphries S.E., Talmud P.J., Montgomery H.E. (London, UK)	22
17.20 – 17.35	A NOVEL PPAR-gamma MUTATION (R357X), ASSOCIATED WITH PARTIAL LIPODYSTROPHY, HELPS DEFINE THE PHENOTYPE OF THE HUMAN PPAR-gamma LIGAND RESISTANCE (PLR) SYNDROME Agostini M. , Rajanayagam O., Smith A.G., Savage D.B., Clarke M., Zalin A.M., O'Rahilly S., Trembath R.C., Chatterjee V.K.K., Gurnell M. (Cambridge, Wordsley, and Leicester, UK)	22
17.35 – 17.50	IMPACT OF PPAR-gamma2 POLYMORPHISMS ON GLUCOSE TOLERANCE AND INSULIN LEVELS IN TWINS Andersen G. , Poulsen P., Fenger M., Hansen T., Echwald S., Vølund A., Beck-Nielsen H., Vaag A., Pedersen O. (Gentofte, Odense, and Hvidovre, Denmark)	23
17.50 – 18.05	A GENETIC APPROACH TOWARDS UNDERSTANDING THE ROLE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR delta IN MAN Skogsberg J., Kannisto K., McMahon A.D., Eriksson P., Lindblom A., Packard C., Hamsten A., Ehrenborg E. (Stockholm, Sweden and Glasgow, UK)	23
18.05	<i>End of the Session</i>	

Workshop

CLINICAL APPLICATIONS OF PPAR LIGANDS IN THE METABOLIC SYNDROME AND DIABETES

Chairpersons: **Kraegen E.W.** (Sydney, Australia)
Robins S.J. (Boston, USA)

hour:		abstract bk. page ref.:
14.00 – 14.20	PPARs AND THE FATE OF FATTY ACIDS IN THE METABOLIC SYNDROME - HOW WELL IS THE LIPID STEAL HYPOTHESIS HOLDING UP IN 2003? Kraegen E.W. , Ye J.M., Cleasby M., Dzamko N., Hegarty B., Furler S., Cooney G. (Sydney, Australia)	24
14.20 – 14.35	PIOGLITAZONE IMPROVES CONDUIT ARTERY ENDOTHELIAL FUNCTION IN TYPE 2 DIABETES Martens F.M.A.C. , Visseren F.L.J., de Koning E.J.P., op 't Roodt J., Rabelink T.J. (Utrecht, The Netherlands)	24
14.35 – 14.50	EFFECT OF ROSIGLITAZONE OR METFORMIN MONOTHERAPY ON INSULIN-MEDIATED HEPATIC GLUCOSE UPTAKE IN TYPE 2 DIABETES Iozzo P. , Hällsten K., Oikonen V., Virtanen K.A., Kempainen J., Solin O., Ferrannini E., Knuuti J., Nuutila P. (Turku, Finland and Pisa, Italy)	25
14.50 – 15.05	ROSIGLITAZONE BUT NOT METFORMIN ENHANCES INSULIN STIMULATED MYOCARDIAL GLUCOSE UPTAKE IN PATIENTS WITH TYPE 2 DIABETES Hällsten K., Virtanen K.A., Lönnqvist F., Janatuinen T., Rönnemaa T., Viikari J., Knuuti J., Nuutila P. (Turku, Finland and Stockholm, Sweden)	25
15.05 – 15.20	EFFECTS OF ROSIGLITAZONE ON INSULIN SENSITIVITY, LIVER FAT AND GENE EXPRESSION IN SUBCUTANEOUS ADIPOSE TISSUE IN PATIENTS WITH HIV-LIPODYSTROPHY Sutinen J. , Korshennikova E., Kannisto K., Ehrenborg E., Fisher R., Gertow K., Vidal H., Virkamäki A., Nyman T., Hamsten A., Yki-Järvinen H. (Helsinki, Finland, Stockholm, Sweden, and Lyon, France)	25
15.20	<i>End of the Session</i>	

Workshop

PPARs IN CNS

Chairpersons: **Bordet R.** (Lille, France)
Feinstein D.L. (Chicago, USA)

hour:		abstract bk. page ref.:
14.00 – 14.20	PPARs: A NEW PHARMACOLOGICAL TARGET IN CEREBROVASCULAR AND NEURODEGENERATIVE DISEASES? Bordet R. (Lille, France)	25
14.20 – 14.40	NEUROPROTECTIVE ROLES FOR PPAR AGONISTS IN BRAIN: THERAPEUTIC IMPLICATIONS FOR MS AND AD Feinstein D.L. (Chicago, USA)	26
14.40 – 14.55	PPAR-gamma THIAZOLIDINEDIONE AGONISTS INCREASE GLUCOSE METABOLISM IN ASTROCYTES Dello Russo C. , Gavriyuk V., Weinberg G., Almeida A., Bolanos J.P., Galea E., Feinstein D.L. (Chicago, USA)	26
14.55 – 15.10	PPAR-gamma - AGONISTS REDUCES NEUROINFLAMMATION AND beta-AMYLOID LEVELS IN APP (V717) TRANSGENIC MICE Heneka M.T., Dumitrescu-Ozimek L., Kreutz A., Dewachter I., Kuiperi C., van Leuven F., Landreth G. (Bonn, Germany, Leuven, Belgium, and Cleveland, USA)	26
15.10 – 15.25	A ROLE OF SCAVENGER RECEPTOR BI, ENDOTHELIAL LIPASE AND FATTY ACID TRANSLOCASE/CD36 IN PUFA SUPPLY AT THE BLOOD-BRAIN BARRIER Sovic A. , Panzenboeck U., Balazs Z., Goti D., Hrzenjak A., Kostner G.M., Sattler W. (Graz, Austria)	26
15.25	<i>End of the Session</i>	